XNASOLMA
Market cap374mUSD
Jan 10, Last price
5.04USD
1D
-12.35%
1Q
-57.07%
IPO
-89.69%
Name
Olema Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
26.27%
Rev. gr., 5y
%
Revenues
0k
Net income
-97m
L-5.78%
CFO
-84m
L+2.03%
Earnings
Mar 10, 2025
Profile
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 105,338 | 108,646 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (105,338) | (108,646) | ||||
NOPBT Margin | ||||||
Operating Taxes | (2,201) | |||||
Tax Rate | ||||||
NOPAT | (105,338) | (106,445) | ||||
Net income | (96,655) -5.78% | (102,586) 44.72% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 129,736 | 330 | ||||
BB yield | -20.44% | -0.34% | ||||
| Debt | ||||||
Debt current | 1,976 | 1,015 | ||||
Long-term debt | 3,846 | 4,115 | ||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | (255,985) | (199,291) | ||||
| Cash flow | ||||||
Cash from operating activities | (83,727) | (82,065) | ||||
CAPEX | (363) | |||||
Cash from investing activities | (4,851) | 91,479 | ||||
Cash from financing activities | 133,415 | 476 | ||||
FCF | (104,622) | (105,700) | ||||
| Balance | ||||||
Cash | 261,807 | 204,421 | ||||
Long term investments | ||||||
Excess cash | 261,807 | 204,421 | ||||
Stockholders' equity | (305,281) | (210,787) | ||||
Invested Capital | 562,581 | 410,831 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 45,247 | 39,995 | ||||
Price | 14.03 472.65% | 2.45 -73.82% | ||||
Market cap | 634,817 547.85% | 97,989 -73.51% | ||||
EV | 378,832 | (101,302) | ||||
EBITDA | (104,961) | (108,289) | ||||
EV/EBITDA | 0.94 | |||||
Interest | 357 | |||||
Interest/NOPBT | ||||||